Pharming Group (NASDAQ:PHAR) Cut to “Strong Sell” at Zacks Research

Zacks Research lowered shares of Pharming Group (NASDAQ:PHAR) from a hold rating to a strong sell rating in a report issued on Thursday,Zacks.com reports.

A number of other brokerages have also commented on PHAR. HC Wainwright set a $37.00 price objective on Pharming Group and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings restated a “hold (c-)” rating on shares of Pharming Group in a report on Monday, December 22nd. Wall Street Zen raised Pharming Group to a “strong-buy” rating in a research report on Saturday, December 27th. Finally, Oppenheimer reiterated an “outperform” rating and set a $41.00 price target (down from $42.00) on shares of Pharming Group in a report on Friday. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $39.00.

Pharming Group Price Performance

Shares of NASDAQ PHAR opened at $14.51 on Thursday. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.16 and a quick ratio of 2.39. The business has a fifty day moving average price of $17.21 and a two-hundred day moving average price of $16.07. Pharming Group has a fifty-two week low of $7.50 and a fifty-two week high of $21.34. The stock has a market capitalization of $1.02 billion, a PE ratio of 1,451.00 and a beta of 0.04.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, March 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.08). The business had revenue of $106.50 million for the quarter, compared to analyst estimates of $111.76 million. Pharming Group had a net margin of 0.71% and a return on equity of 1.12%. As a group, equities analysts predict that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC bought a new position in shares of Pharming Group during the 2nd quarter worth approximately $32,000. SmartHarvest Portfolios LLC bought a new position in shares of Pharming Group in the fourth quarter valued at approximately $224,000. Millennium Management LLC purchased a new stake in shares of Pharming Group during the fourth quarter valued at approximately $360,000. Finally, NewEdge Advisors LLC increased its position in shares of Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after acquiring an additional 28,615 shares during the last quarter. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Trending Headlines about Pharming Group

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Company set a 2026 revenue target of $405M–$425M, citing growth from Joenja and RUCONEST as primary drivers — this provides clear growth levers for next year and supports upside if execution meets targets. Pharming outlines $405M–$425M 2026 revenue target
• Positive Sentiment: Company reported full-year and Q4 2025 revenue growth and positive cash flow and reaffirmed 2026 guidance — fundamentals showing improving cash generation can reduce funding risk and support valuation. Pharming Group reports fourth quarter and full year 2025 financial results
• Positive Sentiment: Oppenheimer reiterated an “Outperform” rating with a $41 price target (slightly trimmed), signaling continued bullish analyst conviction and implying substantial upside from current levels. Oppenheimer reaffirms outperform on PHAR
• Neutral Sentiment: HC Wainwright maintains a Buy rating and $37 target but lowered FY2026 EPS from $0.49 to $0.35 — the firm still expects material 2026 profitability, but the cut shows some model uncertainty around timing and magnitude of margin expansion. HC Wainwright updates estimates for PHAR
• Negative Sentiment: Q4 results missed expectations: revenue $106.5M vs. analyst ~$111.8M and EPS $0.07 vs. $0.15 expected — the quarter’s misses likely triggered the intraday sell-off despite upbeat guidance. Pharming Q4 2025 press release

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.